London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I hear you loud and clear Rich and I agree with everything you just said. I'm guilty of a lot of it myself.
CityTTrader - You're clearly just missing the point. We can move on though - save filling the board with a back and forth.
I have no idea what you're talking about. g went to just ovve 400p not 3200p. The risk t the time WaS how much oil. Much laTer it became political I was out long before then.
eva - you missed the point completely. I'm certainly not here for the drama and couldn't care less about earning the likes of people. It's easy to tell people what they want to hear - most of the time it's not popular or right though. I certainly don't do that :p
As for your "buying against acacia"......does that just mean you timed your buys really badly (back in the 70-80p range before it fell to 35pish)? Or are you trying to suggest you were the only member buying down at 35p in the period Acacia started dumping (which quite clearly isn't the case - as I bought in then as remember having to tell many people not to panic about that - on both occasions that they dumped it back down to the 35p level).
I don't give a monkeys if Ghia is 80% here. Your investment strategy seems to be reading what a few people post on a messageboard and then doing something reckless based upon it. That's a very fast way to lose all your money unless you get incredibly lucky. So far you have :p
CityTTrader - I couldn't disagree more. Your post is hindsight trading. Much like Eva's. GKP could easily have had real-world political unrest/violence or countless other problems that could have made it near worthless overnight. Let's not forget it fell thousands of percent from over 3200p to not much over 100p The market wasn't wrong. The market prices in risk. If the risk factors don't happen that doesn't make them wrong. That's not to say that you can't spot opportunities and back them more heavily. I'm not against that myself hence I had my largest position here when it was 6p. However advising people to go all-in on shares like they're sure things is pretty much always dangerously reckless.
And don’t forget that, from the Company in the March placing document, things were going well in the (paused) COPD trial:
SNG001 Phase II trial in COPD
Synairgen is now close to completing a Phase II study in COPD patients with confirmed respiratory viral infections and pre-existing significant impairment of lung function. With 109 out of a target 120 participants already dosed, this trial has been paused to minimise the chance of vulnerable patients being exposed to further infection risk and to minimise distraction for respiratory staff in the UK hospitals and GP sites conducting the trial, who will be at the forefront in dealing with patients suffering from COVID-19. The Company is currently exploring ways to adapt the trial to enable patients in the pre-treatment pool to be dosed if they become infected with SARS-CoV-2.
Early data from this double-blind, placebo-controlled trial have demonstrated that the antiviral responses in the lung (assessed using sputum biomarkers) are similar to those observed in the asthma trial, where we saw clinical benefit in lung function.
Rich
I would say that every now and again a share comes along which just has to be all in. Back in 2008 it was TW. Aviva sold their entire holding at 4p. A massive loss but a great opportunity. TW was values at 100m yet its assets were 4bn. It had debt 1bn and property prices were falling. I reckoned that even if the assets were down to 2bn it was a ten bagger. So I bought and continued to buy up to 20p. Within 6 months it was at 50p. That is the time to buy and go all in when you know the market is wrong.
My next investment all in was when GKP were drilling at a site where oil was seeping out of a hill side. Exactly how BP first found oil. I went all in at 17p. The find was staggering and I sold at 123p far too early but a hell of a ride.
Now SNG. A great product for COPDthat's been cooking for some time and about to come good with an extra kicker that covid 19 has arrived and we are well placed to beat everyone to a potential cure. I would be all in but I need some diversity to keep my nest egg safe too.
I always find the rewriting of history on this board rather interesting :)
The post from Trinityman gets more likes than almost any other yet it's rather wonky with a lot of the information.
How could I forget my argument with Nolupus about RM's interview on Jun 19th the day before the big RNS:
https://www.lse.co.uk/ShareChat.asp?ShareTicker=SNG&share=Synairgen&page=559 (in 25 posts per page view)
Still doing alright at the poker too ;)
Im hoping that azn are going to buy us out at 3bn, they are raising this amount through bonds and have recently released a statement in relation to concentrating efforts on copd. I’m still holding my original investment and topped up at 202. My investment is by no means massive but a ten bag would be a life changer. I’m going long the possible rewards at buyout far out way the risks in my opinion. It worked on sars and mers has shown promising results on covid 19 (peer review due soon) what are the odds it will work for common lung infections for copd or asthma, very high in my opinion. Good luck to all investors
Everyone has a different attitude to risk/ reward Ray, I originally held Just over 60k shares, I now hold 30k and have banked a tidy sum. Great respect to those who are holding for even bigger gains, but I’m very happy how this has turned out so far.
Love it Trinityman, what a ledge
There has been some great posts on this board over the last few months but Trinityman has just topped the lot, A brilliant summary of the potential of this company.
One day you may decide to just hold!
Hold for gold!
I once had almost 300k shares and couldnt resist the pay day... now holding 7% of that, no doubt one day I'll add up the cost of that decision but profit is profit..
I just look at what’s currently available as a treatment for copd, asthma basically viral infections Seasonal flu, new strains of future covid etc
By 2022 COPD will be a 20B market a year on its own
I expect SNG001 will prove far more effective than what’s currently available and will be the go to drug
Is there any competition on the horizon? Yes
but I can only think of 1 in Canada also neb using ifn b
Is there opportunity realistically for SNG to take 10% market share based on what alternative treatments are available? Absolutely that’s 2B just on copd a year
Example of viral treatment drug, symbicort for AZN generates 700m a year.
The top 3 new revenue drugs this year are all forecast to earn 1.5 billion a year Within the next 3 years and the top one is for migraines not a life saving drug
Factor in covid and shelf life, stockpiling
I’m beginning to think I’ve low balled the buyout actually
Last year biggest buyout was 11B no covid maybe it will be 15B this year when we got bought who knows
This won't help with Asthma im afraid, unless those with asthma get a viral infection.
And of course we can hopefully add asthma to the package as well !!
I’ve been here since beginning of March and have posted multiple times Sharing research I’ve found myself.
I did all the links, the common sense and the facts all the way through clearly stating numerous occasions “if it goes to 10p it doesn’t matter all that matters is I keep building my holdings until those results come out”
I have posted even more, sharing articles and my own thoughts etc on social media investing groups than I have on here and have gotten a rather large following
Now I prefer more light hearted posts, I’m confident in what I’ve read up back in Feb, confident sng will deliver and even more confident that the share price will be between £13.50 - £33.50
A 3 billion buyout equates to roughly £20 a share
TrinityMan
#Legend
#Synairgen #GoodTimes #GolfTomorrowAndNewsWillComeOnTheSixthHoleAGAIN
TrinityMan
Synairgen has been a fantastic experience. I agree there has and continues to be some outstanding knowledge and posters. Back in Feb / March we all researched Synairgen and similar companies and reviewed research from across the world. As we built our knowledge pool the a picture developed and I think we all added more than normal into the SNG pot. I remember many doubters and trolls tried to weaken our mindset. We faced a huge headwind of three sellers and a placing. In that time the share price reached 70p and then dropped to a low around 32p. What a ride.
It was the team effort that kept me focused, that and the outstanding team at Synairgen. As world trials using Interferons increased and results started to appear more
And more positive, our belief increased and so did the displeasure of the trolls! Then mad Monday happens, I think I will remember that day until I die. 7am RNS the headline 3 statements were MASSIVE! That day made the last 8 years of AIM PAIN worth it.
Looking forward I will again show some caution and warn anything can happen this is AIM. However I, like many others, believe this is worth a minimum £1billion at take over. £6.33 per share. I expect to see COPD results soon. Let’s not get disappointed if they don’t land tomorrow, as RM confirmed there are multiple data points against multiple virus. FDA and MHRA emergency applications must also being expedited. Let’s also not forget our friends in Auss. LOXL2 has huge potential still and news is due there as well.
Like most I have sold some of my holding. However I had to keep some skin in the game and I believe we won’t be disappointed.
Sleep well all and here is to a fantastic month for all still invested.
We are all fixated, understandably with COVID, but COPD and other conditions will potentially benefit from SNG001. As sure as eggs, another respiratory virus will be along within the next 5-6 years and SNG001 is going to be well placed to deal with that too. Could well end up being a drug which is stockpiled by governments around the world. First, I’m looking forward to seeing it used for the immediate benefit of people suffering.
Trinity man ,
Well done for your post .
The real danger here was before trial results because no matter how much we believed in the science , Synairgen had everything to prove to the world as well as to the investors . I would'nt have invested here , only for COvid or at least after a succesful readout in the phase 2 COPD .
The Covid 19 has put Synairgen under the spotlight but I agree it's COPD which will now bring real rewards if succesful .The road is still long with many milestones to meet , but every milestone will bring extra value to those that are patient .
Extraordinary times .....
I’m sticking with a 3b buyout . If you look at the potential global market for COPD and now COVID .......... it’s cheap imo !!
Excellent post.
This has potentially significant value long term just to alleviate COPD because that population worldwide is also so big. Short term, it's the potential impact on COVID and restoring world economies where this is going to be so big in demand. Horrible circumstances for those that have suffered but is potentially creating the perfect storm for SYN and whoever they partner with. So I'd be surprised if it's not more than £7.50. I have no idea but a sensible share of global licensing rights paid for by all the governments desperate to reassure their voters and reopen economies pushes it further North than that - perhaps some patience through the winter
Trinityman:
Applause to you for an excellent and interesting post...